Table 1.
Responses of type 1 diabetes control patients and diabetes patients submitted to total pancreatectomy (TP) to general quality of life measures as assessed by the European Organization for the Research and Treatment of Cancer (EORTC) core quality of life questionnaire QLQ-C30 and pancreas-specific supplementary module PAN26
| Item | Cohort score, median (IQR) | P-value | |
|---|---|---|---|
| Control group | TP group | ||
| (n = 23) | (n = 23) | ||
| QLQ-C30 functional scales | |||
| Physical status | 100 (86.6–100) | 66.7 (43.3–86.6) | <0.001b |
| Working ability | 100 (91.7–100) | 66.7 (41.7–83.3) | 0.013a |
| Cognitive functioning | 100 (83.3–100) | 66.7 (33.3–91.7) | 0.009a |
| Emotional functioning | 83.3 (66.7–95.8) | 66.7 (50.0–95.8) | 0.204 |
| Social functioning | 100 (66.7–100) | 66.7 (33.3–100) | 0.019a |
| Global quality of life | 66.7 (50.0–83.3) | 58.3 (29.2–70.8) | 0.109 |
| QLQ-C30 symptom scales | |||
| Fatigue | 11.1 (0–27.8) | 44.4 (33.3–72.2) | 0.003b |
| Nausea and vomiting | 0 (0–0) | 0 (0–16.7) | 0.013a |
| Pain | 0 (0–25) | 16.7 (0–50.0) | 0.191 |
| Dyspnoea | 0 (0–16.7) | 0 (0–33.3) | 0.336 |
| Insomnia | 33.3 (0–33.3) | 66.7 (33.3–100) | 0.008a |
| Appetite loss | 0 (0–33.3) | 0 (0–66.7) | 0.219 |
| Constipation | 0 (0–0) | 0 (0–33.3) | 0.959 |
| Diarrhoea | 0 (0–0) | 0 (0–33.3) | 0.070 |
| Financial difficulties | 0 (0–16.7) | 33.3 (0–50.0) | 0.147 |
| PAN26 symptom scales | |||
| Pancreas-specific pain | 8.3 (4.2–26.7) | 33.3 (22.5–62.5) | 0.011a |
| Diet restriction | 16.7 (0–33.3) | 50 (25.0–66.7) | 0.007a |
| Jaundice and pruritus | 0 (0–16.7) | 16.7 (0–33.3) | 0.006a |
| Steatorrhoea | 16.7 (0–33.3) | 50 (33.3–66.7) | 0.05 |
| Poor body image | 16.7 (0–50.0) | 16.7 (0–58.3) | 0.716 |
| Sexual dysfunction | 33.3 (0–66.7) | 33.3 (0–100) | 0.322 |
| Dissatisfaction with health care | 66.7 (25–83.3) | 66.7 (41.7–100) | 0.392 |
| Bloating | 0 (0–0) | 33.3 (0–66.7) | 0.001b |
| Bad tasting food | 0 (0–0) | 0 (0–33.3) | 0.003b |
| Indigestion | 0 (0–0) | 0 (0–33.3) | 0.103 |
| Flatulence | 0 (0–33.3) | 33.3 (0–83.3) | 0.006a |
| Difficulty gaining weight | 0 (0–0) | 0 (0–16.7) | 0.327 |
| Weakness | 0 (0–33.3) | 33.3 (16.7–66.7) | 0.016a |
| Dry mouth | 0 (0–33.3) | 66.7 (16.7–66.7) | 0.008a |
| Treatment side-effects | 0 (0–33.3) | 33.3 (0–50.0) | 0.020a |
| Worry about health care in the future | 33.3 (16.7–66.7) | 33.3 (33.3–66.7) | 0.500 |
| Difficulty in planning future events | 0 (0–16.7) | 0 (0–33.3) | 0.264 |
On the functional scales, a higher value represents higher quality of life; on the symptom scales, a higher value represents worse symptoms (range: 0–100).
a
Significance at P < 0.05, Wilcoxon signed ranks test.
b
Significance with Bonferroni correction (P < 0.0033 for QLQ-C30 responses and P < 0.0029 for PAN26 responses).
IQR, interquartile range.